Development of specific therapy for poor prognosis subtypes of pancreatic cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K18079
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Watanabe Shuichi 東京医科歯科大学, 東京医科歯科大学病院, 助教 (20771827)
• Project Period (FY): 2021-03-01 – 2024-03-31
• Keywords: 膵癌 / エピゲノム / 化学療法 / KDM6A

Outline of Final Research Achievements

In this study, we examined the clinical significance of KDM6A expression using public databases and clinical specimens, and performed functional analysis in human pancreatic cancer cell lines. The study revealed that DM6A inactivation is associated with (1) K poor prognosis pancreatic cancer subtype, (2) malignant transformation of pancreatic cancer cell lines, (3) H3K27ac reduction in the promoter region of tumor suppressor genes, and (4) HDAC inhibitors have specific effects.

Free Research Field

肝胆膵外科学

Academic Significance and Societal Importance of the Research Achievements

肝胆膵領域の難治癌においてサブタイプを決定づけるエピゲノム修飾遺伝子の変異およびその分子生物学的機能についてトランスレーショナルリサーチによって解明することができ、治療薬開発につながる知見が得られた。